[Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F Fourth Quarter and Full Year 2019 Financial Summary Ÿ Sales for the fourth quarter of 2019 were $81.1 million, an increase of 52.4% from $53.2 million in the prior year period. Ÿ Sales in 2019 w]
[CONTENTS] [SPECIMEN * NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT * INCORPORATED UNDER THE LAWS OF THE GOVERNMENT OF ANTIGUA Number Sinovac Shares BIOTECH LTD. This Certifies that Is the Owner of Fully paid and non-assessable shares of Common Stock of Sinovac Biotech Ltd. transferable on the bo]
[CONTENTS] [SPECIMEN * NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT * INCORPORATED UNDER THE LAWS OF THE GOVERNMENT OF ANTIGUA Number Sinovac Shares BIOTECH LTD. This Certifies that Is the Owner of Fully paid and non-assessable shares of Common Stock of Sinovac Biotech Ltd. transferable on the bo]
[Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F Fourth Quarter and Full Year 2019 Financial Summary Ÿ Sales for the fourth quarter of 2019 were $81.1 million, an increase of 52.4% from $53.2 million in the prior year period. Ÿ Sales in 2019 w]
[Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19 BEIJING --(BUSINESS WIRE)-- April 17, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Compa]
[Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19 BEIJING --(BUSINESS WIRE)-- April 17, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Compa]
[Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19 BEIJING--(BUSINESS WIRE)-- April 14, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company has obta]
[Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19 BEIJING--(BUSINESS WIRE)-- April 14, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company has obta]
[] [Loans Extension Confirmation Letter Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD111,940.95 respectively as of December 31, 2019. Due to the fact the Company temporarily di]
[] [Loans Extension Confirmation Letter Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD111,940.95 respectively as of December 31, 2019. Due to the fact the Company temporarily di]
